Font size
Background and font color
Images
Text scoring
Regular version of the site
Research Institute of Influenza
Готовое решение для
медицинского центра
+7* (*81*2)* 4*99*-1*5-*00
+7* (*81*2)* 4*99*-1*5-*00 Telephone and fax
Email
o*ff*ice*@in*flue*nz*a.spb*.ru
The address
197022 St. Petersburg st. prof. Popova 15/17
Working hours
Mon. – Fri .: from 9:00 to 18:00
Подать заявку
The Institute
  • Organization Structure
  • About the Institute
  • Contact us
Research & Innovations
  • Research Areas
  • Publications
  • Innovations
Influenza Surveillance
  • Influenza Surveillance in Russia
  • Influenza Bulletin
  • RSV Bulletin
News & Events
  • News
  • Announcements
  • Conferences
  • Gallery
Contact us
en
ru
en
Research Institute of Influenza
"/>
en
ru
en
The Institute
Research & Innovations
Influenza Surveillance
News & Events
Contact us
    Research Institute of Influenza
    Telephones
    +7* (*81*2)* 4*99*-1*5-*00 Telephone and fax
    Email
    o*ff*ice*@in*flue*nz*a.spb*.ru
    The address
    197022 St. Petersburg st. prof. Popova 15/17
    Working hours
    Mon. – Fri .: from 9:00 to 18:00
    Research Institute of Influenza
    • The Institute
      • The Institute
      • Organization Structure
        • Organization Structure
        • Administration
        • Department of Biotechnology
          • Department of Biotechnology
          • Laboratory of Biotechnology of Diagnostic Reagents
          • Laboratory of Cell Cultures
          • Laboratory of Genetic Engineering and Recombinant Protein Expression
        • Department of Vaccinology
          • Department of Vaccinology
          • Laboratory of Influenza Vaccines
          • Laboratory of Vector Vaccines
        • Department of Molecular Biology of Viruses
          • Department of Molecular Biology of Viruses
          • Laboratory of Intercellular Signaling and Transport
          • Laboratory of Molecular Diagnostic Systems
          • Laboratory of Systems Virology
        • Department of Etiology and Epidemiology
          • Department of Etiology and Epidemiology
          • Laboratory of Influenza Evolutionary Variability
          • Laboratory of Influenza and Acute Respiratory Illness Epidemiology
          • Laboratory of Molecular Virology
          • Laboratory of Acute Respiratory Viral Infection Risk Factor Assessment
        • Laboratory of Molecular Modelling and Bioinformatics
        • Department of Preclinical Trials
          • Department of Preclinical Trials
          • Laboratory of Drug Safety
          • Laboratory of Chemotherapy for Viral Infections
        • Clinical Department
      • About the Institute
      • Contact us
    • Research & Innovations
      • Research & Innovations
      • Research Areas
      • Publications
      • Innovations
    • Influenza Surveillance
      • Influenza Surveillance
      • Influenza Surveillance in Russia
      • Influenza Bulletin
    • News & Events
      • News & Events
      • News
      • Announcements
      • Conferences
      • Gallery
    • Contact us
    • en
      • Language
      • en
      • ru
    • +7* (*81*2)* 4*99*-1*5-*00 Telephone and fax
      • Telephones
      • +7* (*81*2)* 4*99*-1*5-*00 Telephone and fax
    • 197022 St. Petersburg st. prof. Popova 15/17
    • o*ff*ice*@in*flue*nz*a.spb*.ru
    • Mon. – Fri .: from 9:00 to 18:00

    Influenza Bulletin

    Main
    >
    Surveillance
    >Influenza Bulletin

    NATIONAL WEEKLY INFLUENZA BULLETIN OF THE RUSSIAN FEDERATION

    week 19 of 2025 (05.05.25 - 11.05.25)

    Summary

    Influenza and ARI incidence data. Influenza and other ARI activity in Russia decreased in comparison with previous week. The nationwide ILI and ARI morbidity level (35.6 per 10 000 of population) was lower than national baseline (89.9) by 60.4%.

    Etiology of ILI & ARI. Among 6326 patients investigation 444 (7.0%) respiratory samples were positive for influenza, including 75 cases of unsubtyped influenza A in 11 cities, 47 cases of influenza A(H1N1)pdm09 in 17 cities, 14 cases of influenza A(H3N2) in 6 cities and 308 cases of influenza B in 34 cities.

    24 influenza viruses were isolated on MDCK cell culture, including 6 cases of influenza A(H1N1)pdm09 in Saint-Petersburg and 18 cases of influenza B in Veliky Novgorod (2), Novosibirsk (1), Saint-Petersburg (15). Since the beginning of the season 920 influenza viruses, including: 421 A(H1N1)pdm09 viruses, 35 - A(H3N2) and 464 influenza B viruses.

    Antigenic characterization. Since the beginning of the season 412 influenza have been antigenically characterized by the NICs, including: 221 influenza A(H1N1)pdm09, 24 influenza A(H3N2) and 167 influenza B viruses. 219 A(H1N1)pdm09 viruses were similar to the reference strain A/Victoria/4897/22 recommended in the vaccines for the Northern Hemisphere countries for the 2024-2025 season, 2 A(H1N1)pdm09 strain reacted to a 1:8 homologous titer with serum to the vaccine strain. 23 A(H3N2) strain were similar to the vaccine strain A/Thailand/8/22, one interacted to 1:8 homologous titer with serum to the A/Thailand/8/22 vaccine strain. 127 influenza B viruses were similar to the vaccine strain B/Austria/1359417/2021, 2 strains were drift variants and reacted to 1:8 homologous titer with serum to the vaccine strain.

    Genetic analysis. Sequencing of 386 influenza A(H1N1)pdm09 viruses of the season 2024-2025 showed that all of them fell within clade 6B.1A.5a.2a, subclade C.1.9. 12 influenza A(H3N2) viruses belonged to clade 3c.2a1b.2a.2a.3a.1 (vaccine virus A/Thailand/8/2022-like), subclade J.2. 63 influenza B strains belonged to Victoria lineage, subclade V1A.3a.2 (B/Austria/1359417/2021-like). By genotypic testing all 461 influenza A and B viruses were susceptible to oseltamivir and zanamivir.  

    Susceptibility to antivirals. Since the beginning of the season 2024-2025, the sensitivity of 446 influenza viruses to neuraminidase inhibitors (oseltamivir, zanamivir) were studied in NIC Saint-Petersburg, including: 254 A(H1N1)pdm09 influenza viruses, 10 A(H3N2) influenza viruses and 182 influenza B viruses. All studied viruses were sensitive to neuraminidase inhibitors.  

    ARVI detections. The overall proportion of respiratory samples tested positive for other ARVI (PIV, ADV, RSV, RhV, CoV, MPV, BoV) was estimated in total as 19.9% (PCR).

    In sentinel surveillance system clinical samples from 23 SARI patients were investigated by rRT-PCR for influenza, among them 1 (4.3%) case of influenza В was recognized. Among 23 SARI patients no positive cases of coronavirus SARS-CoV-2 recognized. Among 23 SARI samples 3 (13.0%) cases positive for ARVI were detected, including: 1 case of RSV and 2 cases of RhV infection.

    Clinical samples from 8 ILI/ARI patients were investigated by rRT-PCR for influenza, among them 1 (12.5%) case of influenza В was recognized. Among 8 ILI/ARI samples 3 (37.5%) cases of RhV infection were detected. Among 8 ILI/ARI patients no positive cases of coronavirus SARS-CoV-2 recognized.

    COVID-19. The Federal Operational Headquarters for Combating the Novel Coronavirus Infection has discontinued the publication of weekly COVID-19 morbidity reports starting from epidemiological week 12. This decision is due to the stabilization of the epidemiological situation regarding COVID-19 and the transition of the virus to the category of seasonal respiratory infections.

    According to the data obtained by NIC in Saint-Petersburg totally 7219 clinical samples were PCR investigated in last week. Among them coronavirus SARS-CoV-2 detected in 32 (0.4%) cases.

    Influenza and ARI morbidity data

    Fig. 1. Influenza and ARVI morbidity in 61 cities under surveillance in Russia, seasons 2023/24 and 2024/25
    Rates per 10 000 population Fig. 1. Influenza and ARVI morbidity in 61 cities under surveillance in Russia, seasons 2023/24 and 2024/25

    Weeks

    • Morbidity 2024/25 Morbidity 2024/25
    • Morbidity 2023/24 Morbidity 2023/24
    • MEM baseline 2024/25 MEM baseline 2024/25

    Epidemiological data showed decrease of influenza and other ARI activity in Russia in comparison with previous week. The nationwide ILI and ARI morbidity level (35.6 per 10 000 of population) was lower than national baseline (89.9) by 60.4%.

    Fig. 2. Comparative data on incidence rate of clinically diagnosed influenza, seasons 2023/24 and 2024/25
    Rates per 10 000 population Fig. 2. Comparative data on incidence rate of clinically diagnosed influenza, seasons 2023/24 and 2024/25

    Weeks

    • Season 2024/25 Season 2024/25
    • Season 2023/24 Season 2023/24
    • MEM baseline MEM baseline

    Incidence rate of clinically diagnosed influenza decreased comparing to previous week and amounted to 0.38 per 10 000 of population, it was higher than pre-epidemic MEM baseline (0.040).

    Fig. 3. Comparison of hospitalization rate with clinical diagnosis of influenza, seasons 2023/24 and 2024/25
    Rates per 10 000 population Fig. 3. Comparison of hospitalization rate with clinical diagnosis of influenza, seasons 2023/24 and 2024/25

    Weeks

    • Season 2024/25 Season 2024/25
    • Season 2023/24 Season 2023/24
    • MEM baseline MEM baseline

    Hospitalization rate of clinically diagnosed influenza decreased comparing to previous week and amounted to 0.095 per 10 000 of population, it was higher than pre-epidemic MEM baseline (0.010).

    Influenza and ARVI laboratory testing results

    Cumulative results of influenza laboratory diagnosis by rRT-PCR were submitted by 48 RBLs and two WHO NICs. According to these data as a result of 6326 patients investigation 444 (7.0%) respiratory samples were positive for influenza, including 75 cases of unsubtyped influenza A in 11 cities, 47 cases of influenza A(H1N1)pdm09 in 17 cities, 14 cases of influenza A(H3N2) in 6 cities and 308 cases of influenza B in 34 cities.

    24 influenza viruses were isolated on MDCK cell culture, including 6 cases of influenza A(H1N1)pdm09 in Saint-Petersburg and 18 cases of influenza B in Veliky Novgorod (2), Novosibirsk (1), Saint-Petersburg (15). Since the beginning of the season 920 influenza viruses, including: 421 A(H1N1)pdm09 viruses, 35 - A(H3N2) and 464 influenza B viruses.

    Antigenic characterization. Since the beginning of the season 412 influenza have been antigenically characterized by the NICs, including: 221 influenza A(H1N1)pdm09, 24 influenza A(H3N2) and 167 influenza B viruses. 219 A(H1N1)pdm09 viruses were similar to the reference strain A/Victoria/4897/22 recommended in the vaccines for the Northern Hemisphere countries for the 2024-2025 season, 2 A(H1N1)pdm09 strain reacted to a 1:8 homologous titer with serum to the vaccine strain. 23 A(H3N2) strain were similar to the vaccine strain A/Thailand/8/22, one interacted to 1:8 homologous titer with serum to the A/Thailand/8/22 vaccine strain. 127 influenza B viruses were similar to the vaccine strain B/Austria/1359417/2021, 2 strains were drift variants and reacted to 1:8 homologous titer with serum to the vaccine strain.

    Genetic analysis. Sequencing of 386 influenza A(H1N1)pdm09 viruses of the season 2024-2025 showed that all of them fell within clade 6B.1A.5a.2a, subclade C.1.9. 12 influenza A(H3N2) viruses belonged to clade 3c.2a1b.2a.2a.3a.1 (vaccine virus A/Thailand/8/2022-like), subclade J.2. 63 influenza B strains belonged to Victoria lineage, subclade V1A.3a.2 (B/Austria/1359417/2021-like). By genotypic testing all 461 influenza A and B viruses were susceptible to oseltamivir and zanamivir. 

    Susceptibility to antiviral. Since the beginning of the season 2024-2025, the sensitivity of 446 influenza viruses to neuraminidase inhibitors (oseltamivir, zanamivir) were studied in NIC Saint-Petersburg, including: 254 A(H1N1)pdm09 influenza viruses, 10 A(H3N2) influenza viruses and 182 influenza B viruses. All studied viruses were sensitive to neuraminidase inhibitors. 

    Fig. 4. Geographic distribution of RT-PCR detected influenza viruses in cities under surveillance in Russia, week 19 of 2025
    Fig. 4. Geographic distribution of RT-PCR detected influenza viruses in cities under surveillance in Russia, week 19 of 2025
    PCR results
    • No data
    • No viruses detected
    • H1pdm09
    • H3
    • H3+H1pdm09
    • B
    • B+H1pdm09
    • B+H3
    • B+H3+H1pdm09
    • A (not subt.)
    • A (not subt.)+H1pdm09
    • A (not subt.)+H3
    • A (not subt.)+H3+H1pdm09
    • A (not subt.)+B
    • A (not subt.)+B+H1pdm09
    • A (not subt.)+B+H3
    • A (not subt.)+B+H3+H1pdm09
    Fig. 5. Monitoring of influenza viruses detection by RT-PCR in Russia, season 2024/25
    Number of positive cases Fig. 5. Monitoring of influenza viruses detection by RT-PCR in Russia, season 2024/25 % positive

    Weeks

    • H1pdm09 H1pdm09
    • H3 H3
    • B B
    • A (not subt.) A (not subt.)
    • % positive % positive
    Fig. 6. Monitoring of ARVI detection by RT-PCR in Russia, season 2024/25
    Number of positive cases Fig. 6. Monitoring of ARVI detection by RT-PCR in Russia, season 2024/25

    Weeks

    • PIV PIV
    • ADV ADV
    • RSV RSV
    • RhV RhV
    • CoV CoV
    • MPV MPV
    • BoV BoV

    ARVI detections. The overall proportion of respiratory samples tested positive for other ARVI (PIV, ADV, RSV, RhV, CoV, MPV, BoV) estimated as 19.9% of investigated samples by PCR.

    Fig. 7. Monitoring of influenza viruses isolation in Russia, season 2024/25
    Number of positive cases Fig. 7. Monitoring of influenza viruses isolation in Russia, season 2024/25 % positive

    Weeks

    • H1pdm09 H1pdm09
    • H3 H3
    • B B
    • % positive % positive

    Table 1. Results of influenza and other ARVI detection by RT-PCR in Russia, week 19 of 2025

      Number of  specimens / number of positive cases  % positive
    Influenza
    Number of specimens tested for influenza 6326 -
    Influenza A (not subt.) 75 1,2%
    Influenza A(H1)pdm09 47 0,7% 
    Influenza A(H3) 14 0,2% 
    Influenza B 308 4,9% 
    All influenza 444 7,0%
    Other ARVI
    Number of specimens tested for ARVI 6296  -
    PIV 94 1,5%
    ADV 73 1,2%
    RSV 222 3,5%
    RhV 561 8,9%
    CoV 121 1,9%
    MPV 162 2,6%
    BoV 19 0,3%
    All ARVI 1252 19,9%
    SARS-CoV-2 (COVID-19)
    Number of specimens tested for SARS-CoV-2 7219 -
    SARS-CoV-2 32 0,4%
    Fig. 8. Results of PCR detections of SARS-CoV-2 in Russia
    Fig. 8. Results of PCR detections of SARS-CoV-2 in Russia
    % positive
    • No data
    • less then 10%
    • 10-20%
    • 20-30%
    • 30-40%
    • 40-50%
    • 50% and more

    COVID-19. The Federal Operational Headquarters for Combating the Novel Coronavirus Infection has discontinued the publication of weekly COVID-19 morbidity reports starting from epidemiological week 12. This decision is due to the stabilization of the epidemiological situation regarding COVID-19 and the transition of the virus to the category of seasonal respiratory infections. According to the data obtained by NIC in Saint-Petersburg totally 7219 clinical samples were PCR investigated in last week. Among them coronavirus SARS-CoV-2 detected in 32 (0.4%) cases.

    Table 2. Results of influenza viruses isolation in Russia, week 19 of 2025

      Number of specimens / number of viruses  % isolated viruses
    Number of specimens 43 -
    Influenza A(H1)pdm09 6 14,0% 
    Influenza A(H3) 0 0,0% 
    Influenza B 18 41,9% 
    All influenza 24 55,8%

    Sentinel influenza surveillance

    Clinical samples from 23 SARI patients were investigated by rRT-PCR for influenza, among them 1 (4.3%) case of influenza В was recognized. Among 23 SARI patients no positive cases of coronavirus SARS-CoV-2 recognized. Among 23 SARI samples 3 (13.0%) cases positive for ARVI were detected, including: 1 case of RSV and 2 cases of RhV infection.

    Among 8 ILI/ARI patients were investigated by rRT-PCR for influenza, among them 1 (12.5%) case of influenza В was recognized. Among 8 ILI/ARI samples 3 (37.5%) cases of RhV infection were detected. Among 8 ILI/ARI patients no positive cases of coronavirus SARS-CoV-2 recognized.

    Fig. 9. Monitoring of influenza viruses detection by RT-PCR among SARI patients in sentinel hospitals, season 2024/25
    Number of positive cases Fig. 9.  Monitoring of influenza viruses detection by RT-PCR among SARI patients in sentinel hospitals, season 2024/25 % positive

    Weeks

    • H1pdm09 H1pdm09
    • H3 H3
    • B B
    • A (not subt.) A (not subt.)
    • % positive % positive
    Fig. 10. Monitoring of influenza viruses detection by RT-PCR among ILI/ARI patients in sentinel polyclinics, season 2024/25
    Number of positive cases Fig. 10.  Monitoring of influenza viruses detection by RT-PCR among ILI/ARI patients in sentinel polyclinics, season 2024/25 % positive

    Weeks

    • H1pdm09 H1pdm09
    • H3 H3
    • B B
    • A (not subt.) A (not subt.)
    • % positive % positive
    Fig. 11. Monitoring of ARVI detection by RT-PCR among SARI patients in sentinel hospitals, season 2024/25
    Number of positive cases Fig. 11.  Monitoring of ARVI detection by RT-PCR among SARI patients in sentinel hospitals, season 2024/25

    Weeks

    • PIV PIV
    • ADV ADV
    • RSV RSV
    • RhV RhV
    • CoV CoV
    • MPV MPV
    • BoV BoV
    Fig. 12. Monitoring of ARVI detection by RT-PCR among ILI/ARI patients in sentinel polyclinics, season 2024/25
    Number of positive cases Fig. 12.  Monitoring of ARVI detection by RT-PCR among ILI/ARI patients in sentinel polyclinics, season 2024/25

    Weeks

    • PIV PIV
    • ADV ADV
    • RSV RSV
    • RhV RhV
    • CoV CoV
    • MPV MPV
    • BoV BoV
    National weekly influenza bulletin of the Russian Federation
    364,6 Kb
    • Influenza Surveillance in Russia
    • Influenza Bulletin
    • RSV Bulletin
    Login to mail
    Employee Login
    +7* (*81*2)* 4*99*-1*5-*00
    +7* (*81*2)* 4*99*-1*5-*00 Telephone and fax
    Email
    o*ff*ice*@in*flue*nz*a.spb*.ru
    The address
    197022 St. Petersburg st. prof. Popova 15/17
    Working hours
    Mon. – Fri .: from 9:00 to 18:00
    o*ff*ice*@in*flue*nz*a.spb*.ru
    197022 St. Petersburg st. prof. Popova 15/17
    © 2025 Research Institute of Influenza
    Privacy Policy
    Version for the visually impaired
    Site map